Trastuzumab Deruxtecan Plus Pertuzumab Reduce a Risk of Progression or Death in First-Line Treatment for HER2-positive Advanced or Metastatic Breast Cancer By Ogkologos - November 3, 2025 278 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DESTINY-Breast09 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Alex Trebek Admits Undergoing Chemo For Stage 4 Pancreatic Cancer Has... May 15, 2019 ΚΑΡΚΙΝΟΣ ΟΥΡΟΔΟΧΟΥ ΚΥΣΤΕΩΣ March 8, 2019 A Follow-Up Not Inferior to Radioiodine Ablation in Patients with Low-Risk... March 23, 2022 3 ways we’re helping teenagers and young adults with cancer April 18, 2023 Load more HOT NEWS Adding Pembrolizumab to Platinum-Based Chemotherapy Improves Survival in Patients with Previously... AI-Supported Mammography Screening Shows Favourable Outcomes Compared with Standard Double Reading Stress-Induced Immune Changes May Help Cancer Spread FDA Approves Capmatinib for Metastatic NSCLC
